Invention Grant
- Patent Title: Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
-
Application No.: US16063047Application Date: 2016-12-16
-
Publication No.: US10761087B2Publication Date: 2020-09-01
- Inventor: Shinichiro Niwa , Dai Ogura , Hidemi Mizunuma , Yoko Arai , Takahiro Kurose , Yoshihiro Takai , Yoko Mitsuguchi , Mariyo Moriya
- Applicant: Link Genomics, Inc. , ROHTO Pharmaceutical Co., Ltd.
- Applicant Address: JP Tokyo JP Osaka
- Assignee: LINK GENOMICS, INC.,ROHTO Pharmaceutical Co., Ltd.
- Current Assignee: LINK GENOMICS, INC.,ROHTO Pharmaceutical Co., Ltd.
- Current Assignee Address: JP Tokyo JP Osaka
- Agency: Foley & Lardner LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7364ad26 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@50adc7da
- International Application: PCT/JP2016/087647 WO 20161216
- International Announcement: WO2017/104833 WO 20170622
- Main IPC: G01N33/50
- IPC: G01N33/50 ; A61K31/436 ; A61K31/192 ; A61K31/38 ; A61K31/404 ; A61K31/421 ; A61K31/426 ; A61K31/47 ; A61K31/41 ; A61K45/00 ; A61P27/02 ; A61K45/06
Abstract:
The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.
Public/Granted literature
Information query
IPC分类:
